<DOC>
	<DOCNO>NCT02562872</DOCNO>
	<brief_summary>The study single centre , randomise , placebo-controlled , double-blind study DSM265 include two cohort healthy male female volunteer age 18 45 year . The study conduct two sequential part ( Cohort 1 Cohorts 2a 2b ) .</brief_summary>
	<brief_title>DSM265 Prophylaxis Plasmodium Falciparum Malaria</brief_title>
	<detailed_description>Cohort 1 : - Controlled human malaria infection Day 0 ( Direct Venous Inoculation 3200 cryopreserved Plasmodium falciparum sporozoite ) - Drug administration Day -3 - 8 subject : 6 DSM265 400 mg : 2 match placebo Clinical safety review Cohort 1 order proceed Cohorts 2a 2b Cohort 2a : - Controlled human malaria infection Day 0 ( Direct Venous Inoculation 3200 cryopreserved Plasmodium falciparum sporozoite ) - Drug administration Day -X ( define follow safety pharmacokinetic data ) - 8 subject : 6 DSM265 400 mg : 2 match placebo Cohort 2b : - Controlled human malaria infection Day 0 ( infect mosquito bite ) - Drug administration Day -X ( define follow safety pharmacokinetic data ) - 8 subject : 6 DSM265 400 mg : 2 match placebo</detailed_description>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<criteria>Good health base medical history physical examination body mass index &gt; 18 &lt; 30kg/m2 Laboratory result without clinically significant finding within 60 day Males must use medically acceptable form contraception dose DSM265/Placebo 120 day Women must nonchild bear potential willing able practice one require continuous acceptable method contraception negative pregnancy test Able &amp; willing comply study requirement throughout study Agree undergo study procedure , attend study visit stay overnight observation require , last followup visit Willing undergo control human malaria infection mosquito bite / inoculation Able willing answer question inform consent correctly , sign inform consent form Reachable constantly mobile phone email throughout study period Refrain blood donation throughout study Willing take atovaquoneproguanil , Chloroquine register antimalarial Any history malaria ; severe reaction mosquito insect bite ; history anaphylaxis Plans travel malaria endemic region study period Previous participation malaria vaccine study control human malaria infection study Participation clinical study within 30 day enrollment plan participate another investigational vaccine/drug research study Breastfeeding planning become pregnant time study Positive Human Immunodeficiency Virus , Hepatitis B C test Any confirmed/suspected immunosuppressive immunodeficient state History serious psychiatric condition may affect participation study , history convulsion , seizure , severe head trauma Symptoms , physical sign laboratory value suggestive systemic disorder History cancer ( except basal cell carcinoma skin ) History arrhythmias document prolonged QTcFinterval ( &gt; 450 msec ) 12lead ECG demonstrate specific abnormality Moderate risk high cardiovascular event within 5 year ( &gt; 10 % ) Positive family history 1st 2nd degree relative &lt; 50 year cardiac disease , history , know active cardiac disease history : psoriasis porphyria may exacerbate chloroquine ; splenectomy , sickle cell anaemia red blood cell disorder ; allergy contraindication chloroquine atovaquoneproguanil Treatment investigational drug within 28 day 5 halflives study medication ; use drug dietary supplement within 7 day 5 halflives prior study medication . Herbal supplement must discontinue least 28 day prior study medication . As exception , acetaminophen ibuprofen may use approve investigator Use prohibit medication Grapefruit product contain grapefruit from28 day study medication throughout study History drug alcohol abuse within 12 month prior dose , laboratory evidence abuse Current smoking 10 cigarette equivalent per day Plan major surgery enrolment study completion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Controlled</keyword>
	<keyword>Human</keyword>
	<keyword>Malaria</keyword>
	<keyword>Infection</keyword>
	<keyword>Healthy</keyword>
	<keyword>Volunteer</keyword>
</DOC>